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Abstract
Background: There is emerging evidence that exercise training could positively impact several of the cardiovascular
risk factors associated with sudden cardiac death amongst patients on haemodialysis. The primary aim of this study is
to evaluate the effect of an intradialytic exercise programme on left ventricular mass.
Method and design: Prospective, randomised cluster open-label blinded endpoint clinical trial in 130 patients with
end stage renal disease on haemodialysis. Patients will be randomised 1:1 to either 1) minimum of 30 min continuous
cycling thrice weekly during dialysis or 2) standard care. The primary outcome is change in left ventricular mass at
6 months, assessed by cardiac MRI (CMR). In order to detect a difference in LV mass of 15 g between groups at 80 %
power, a sample size of 65 patients per group is required. Secondary outcome measures include abnormalities of
cardiac rhythm, left ventricular volumes and ejection fraction, physical function measures, anthropometric measures,
quality of life and markers of inflammation, with interim assessment for some measures at 3 months.
Discussion: This study will test the hypothesis that an intradialytic programme of exercise leads to a regression in left
ventricular mass, an important non-traditional cardiovascular risk factor in end stage renal disease. For the first time this
will be assessed using CMR. We will also evaluate the efficacy, feasibility and safety of an intradialytic exercise
programme using a number of secondary end-points. We anticipate that a positive outcome will lead to both an
increased patient uptake into established intradialytic programmes and the development of new programmes
nationally and internationally.
Trial registration number: ISRCTN11299707 (registration date 5th March 2015).
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Background
Patients on haemodialysis (HD) have extremely high
rates of cardiovascular disease (CVD) related mortality
[1]. US renal data system (USRDS) data suggests it is the
leading cause of mortality in prevalent HD patients,
accounting for 42.3 % of all deaths [2]. There is good
evidence that these excessive rates of CVD are driven by
a different set of processes than in the general population
and attempts to modify traditional cardiac risk factors
have not improved outcomes in HD patients [3]. Accord-
ing to the USRDS database, up to 64 % of all cardiac mor-
tality among HD patients is due to sudden cardiac death
(SCD) or arrhythmias [4] of an order of around 100 times
higher than the background population [5]. Classical ath-
erosclerotic disease is the leading cause of myocardial
ischaemia in the general population [6], but this is not the
case in HD patients, who are subject to a unique set of
factors that change the cardiac environment and lead to
changes that alter cardiac structure and function [7].
These changes are associated with SCD among HD
patients and include: abnormalities in myocardial struc-
ture and function such as left ventricular hypertrophy
(LVH) which is present in 75 % of dialysis patients; inter-
stitial fibrosis and microvascular disease; with chronic vol-
ume overload and large volume ultrafiltration during
dialysis treatments also contributing to the excess burden
of CVD observed [8–10]. The recurrent and frequent
stresses on the heart from ultrafiltration are associated
with an increase in ventricular arrhythmias [11] that asso-
ciate with SCD and raised biomarkers of cardiac myocyte
damage as well as being independent predictors of HD
related cardiac injury [12] and ultimately myocardial fibro-
sis [13]. To date, efforts to address these changes and im-
prove outcomes have concentrated on medical therapies
(e.g. pharmaceutical agents and implantable cardiac defi-
brillators) which are yet to show positive benefits [14] and
studies have also demonstrated significantly increased
mortality rates in HD patients after coronary revascularisa-
tion compared to the general population confirming the
differences in pathogenesis [15], and again highlighting the
limitations of current treatment options for HD patients.
The benefits of exercise for patients on haemodialysis
Exercise is not as commonly-used a therapeutic inter-
vention in HD patients as it is in other chronic diseases,
e.g. cardiac and respiratory patients, and although it is
clear there are a number of potential benefits from exer-
cise in this patient population the quality of evidence is
variable and there are large gaps in the evidence base.
There are several systematic reviews that summarize the
potential cardiovascular benefits of exercise in HD pa-
tients, as well as the likely benefits to dialysis quality,
quality of life and other health related benefits [16, 17].
Exercise interventions have been largely divided into
those that occur between dialysis sessions (interdialytic
exercise) and those that occur during dialysis (intradialy-
tic exercise). Whilst there is evidence that interdialytic
training may yield superior cardio-respiratory adapta-
tions, there is also a much a higher drop-out rate from
such programmes [18, 19]. Intra-dialytic exercise pro-
grammes are associated with significant improvements
in cardio-respiratory reserve compared to control pa-
tients and have very good adherence rates [18].
Cardiovascular disease, exercise and HD patients
In the general population, lifestyle changes that result in
increased physical exercise lower mortality [20]. Unfor-
tunately, HD patients are less active than even sedentary
healthy people with <50 % of HD patients reporting ex-
ercising once a week and unsurprisingly, higher mortal-
ity rates have been shown in such patients [21]. Exercise
training during or outside of dialysis has been shown in
a number of uncontrolled and non-randomised trials to
lead to significant improvements in a number of cardio-
vascular risk factors that predispose to SCD, both trad-
itional and those unique to patients with end stage renal
disease on HD [22–24]. These studies, however, are all
limited by either small sample size, non-randomised or
uncontrolled design and there are no large studies that
have used cardiac MRI (CMR) to assess changes in myo-
cardial structure and function in HD patients who
undergo a structured programme of exercise.
CMR in HD patients
The term uraemic cardiomyopathy has traditionally been
given to a constellation of changes in cardiac structure
and function seen in patients with end stage renal disease
(ESRD) that include: left ventricular hypertrophy, left ven-
tricular dilatation and left ventricular systolic dysfunction.
All of these structural and functional changes have been
shown to associate with poor cardiovascular outcomes
[25, 26]. It is acknowledged that studies which have used
echocardiography have limited accuracy and reproducibil-
ity in defining geometric parameters and indices of sys-
tolic and diastolic function. This may be especially true in
HD patients who are subject to significant changes in car-
diac filling from fluid status [27]; indeed LV mass and cav-
ity size may be overestimated in up to 50 % of dialysis
patients [28]. CMR has been shown in HD patients to be
a reliable technique for LV mass measurement, with excel-
lent intra- and inter-observer variability for end-diastolic
volume, end-systolic volume and LV mass [29]. LV mass is
a proven continuous variable in a graded relationship with
cardiovascular risk [30], and cardiovascular outcomes
improve as LV mass regresses, underlying the importance
of being able to accurately quantify LV mass change in
intervention studies.
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Echocardiography gives only limited information about
tissue characterisation, compared to CMR. The risk of
nephrogenic systemic fibrosis currently precludes the
administration of gadolium-based contrast agents to HD
patients [31]. New native T1 mapping techniques have
been shown to correlate very well with histological colla-
gen percentage in patients with severe aortic stenosis
[32] and native T1 mapping has been shown to be repro-
ducible in patients with Fabry’s disease and amyloidosis
[33, 34]. Native T1 mapping holds great promise in fur-
ther defining pathogenesis and tissue characterisation in
HD patients and patients with ESRD and CKD.
Whilst atheroma related arterial disease remains an
important factor in patients on HD, arteriosclerosis is of
at least equal importance. Arteriosclerosis is a process
characterised by hypertrophy and increased collagen de-
position in the medial layer of the arterial wall, with cir-
cumferential calcification, and commonly occurs in
patients with ESRD and CKD [35]. This causes arterial
stiffness and has been shown to independently predict
cardiovascular morbidity and mortality in ESRD [36].
There is a significant amount of research examining the
relationship between arterial stiffness and cardiovascular
disease in patients with ESRD and CKD, with much of it
derived from applanation tonometry techniques that
measure aortic pulse wave velocity and measures of aor-
tic/arterial distensibility [36–38]. More recently CMR
has been used to assess aortic distensibilty and there is
gathering evidence of both the importance of aortic dis-
tensibility and its relationship with the development of
uraemic cardiomyopathy, as well as the validity of using
CMR for its assessment [39–41].
Myocardial strain and strain rate have been shown to be
early markers of contractile dysfunction in many condi-
tions that precede declines in ejection fraction. Systolic
strain and strain rates have traditionally been assessed
with CMR using tissue tagging techniques [42]. Increased
circumferential basal strain and strain rates and reduced
longitudinal function may occur in non-diabetic CKD
patients, before any other structural or functional changes
are apparent; suggesting it may be a very early indicator of
uraemic cardiomyopathy [43]. Whilst tissue tagging is
proven to be reproducible, scan acquisition requires add-
itional long breath-holds and analysis can be cumbersome.
Newer methods of strain and strain rate analysis are now
available that can assess LV strain and strain rates directly
from cine images. Our group has shown that Feature
Tracking has excellent reproducibility and maybe more
robust than tissue tagging in acute myocardial infarction
patients [44, 45]. There are currently no studies that have
used CMR to assess the effects of exercise on cardiac
structure and function in HD patients.
The primary aim of this study is to investigate the effects
of a six month programme of intra-dialytic exercise on LV
mass as assessed by CMR. We will assess other cardiac
structural and functional end-points, as well as biochem-
ical markers of acute and chronic cardiac dysfunction,
anthropometric measurements and measures of physical
function and quality of life. An important secondary aim
is to establish whether intradialytic exercise training is
associated with an increase in cardiac arrhythmia, thereby
addressing one of the major safety concerns.
Methods
Design
The protocols described in this manuscript are quorate
with the most recent study protocol for the CYCLE-
HD trial (version 3 15/05/2015). This study is a pro-
spective, randomised, open-label, blinded endpoint
(PROBE) study, with cluster design. The trial was given
ethical approval by the NHS Research Ethics Commit-
tee East Midlands (Northampton; REC ref: 14/EM/
1190). We aim to recruit 130 patients with established
renal failure on maintenance HD. The study will ini-
tially take place at three dialysis units within the East
Midlands Renal Network with the provision of an
intradialytic cycling programme being randomised
depending upon shift pattern. This study is a fully
funded National Institute for Health Research (NIHR)
portfolio study ‘CYCLE-HD’ (UKCRNID 17951) and is
registered with the ISCRTN registry (ISRCTN11299707).
Randomisation
Current practice in UK dialysis centres dictates that
patients dialyse in one of two cohorts, either on a
Monday, Wednesday and Friday or Tuesday, Thursday
and Saturday. In this study, each dialysis shift will be
randomised to either continue on standard dialysis
therapy (control group) (see ‘Usual Care: Haemodialy-
sis’ below) or standard dialysis therapy plus the inter-
vention of intradialytic exercise (exercise group). This
method of randomisation was modelled by the Robertson
Biostatistics Centre at the Glasgow Clinical Trials Unit and
peer reviewed by the National Institute of Health Research
(NIHR).
Aims of the study
 To assess the effects of a six-month intra-dialytic
programme of exercise on cardiovascular structure
and function
 To assess the effects of a six-month intra-dialytic
programme of exercise on changes in biomarkers of
cardiovascular disease and systemic inflammation,
physical function, body composition and quality of
life measures
Two sub-studies will:
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 Assess the short-term arrhythmogenic potential of
intradialytic exercise
 Assess the reproducibility of a number of CMR
parameters not previously assessed or validated in
HD patients
Primary hypothesis
 A six month programme of intradialytic exercise will
lead to a regression in LV mass in patients receiving
maintenance HD
Secondary hypotheses
 A six-month intradialytic programme of exercise for
HD patients is safe with no increase in either cardiac
arrhythmias or fibrosis
 A six-month intradialytic programme of exercise leads
to an improvement in CV indices associated with an
increased CV risk and SCD including: LV function;
myocardial fibrosis; LV strain; cardiac arrhythmias;
autonomic dysfunction; raised biochemical markers of
cardiac damage and heart failure and; systemic
inflammation
 A six-month intradialytic programme of exercise leads
to an improvement in physical function and QOL
Outcome measures
Primary outcomes measure:
1. LV mass in grams using CMR
Secondary outcome measures:
1. Cardiac arrhythmias, including frequency; isolated
ectopy as a percentage of the total beats on the
Holter monitor record; ventricular arrhythmias
stratified according to the Lown classification with
classes 3 and above taken as complex; and heart rate
variability. Patients undergoing exercise intervention
will undergo additional 48 h recording to assess
rhythm data, during and after exercise on dialysis.
Interim analysis is planned to identify any
potential adverse rhythm disturbances associated
with exercise
2. Left ventricular end-diastolic and end-systolic
volumes and ejection fraction (%) using CMR
and echocardiography. Measures of systolic and
diastolic dysfunction and myocardial fibrosis
using CMR and ECHO
3. Aortic stiffness: Aortic distensibility and/or pulse
wave velocity
4. Anthropometric measures including, but not limited
to, weight, height and waist circumference
5. Physical function assessed by shuttle walk tests, sit
to stand tests, balance tests and gait speed (the short
physical performance battery)
6. Objective assessments of physical activity using
validated questionnaires and tri-axial accelerometry
7. Quality of life (QOL) using validated questionnaires
8. Blood markers of inflammation, cardiovascular
dysfunction and cardiovascular risk
9. Selected clinical episodes including: all
hospitalisations; all-cause mortality; cardiovascular
mortality; and cardiovascular morbidity including
non-fatal myocardial infarction, cerebrovascular
event, critical limb ischaemia
Participant identification and recruitment
Prevalent adult patients undergoing in-centre mainten-
ance HD at one of the enrolled units are eligible for in-
clusion in the study. Full lists of inclusion and exclusion
criteria are included in Table 1.
Patients will be recruited from centres within the East
Midlands Renal Network, which cares for approximately
820 HD patients across four Counties in the United
Kingdom. The three principal centres in Leicestershire
care for around 350 patients. We anticipate 80 % will
meet the inclusion criteria (320 patients). Conservatively
assuming a 50 % consent/participation rate this will
leave approximately 160 patients from which we will
need to recruit 130.
Consent
Consent will be performed according to the rules of good
clinical practice. The cluster randomisation design of this
trial means that at recruitment researchers will know,
based on the days on which they have dialysis, whether the
patient will be in the control or the intervention group. Al-
though it will become obvious to patients when they com-
mence the trial whether they will be in the control group,
or the intervention group, this will not be explained to
patients before they consent to reduce selection bias. A
copy of the consent form is included as Additional file 1.
Data collection
An electronic case report form (eCRF) will be used to
collect all study data. Only authorised personnel will be
Table 1 Eligibility and Exclusion criteria
Eligibility Criteria Exclusion Criteria
• Prevalent HD patient
(> three months)
• Aged 18 years or older
• Able and willing to give
informed consent
• unable to participate in current exercise
programme due to perceived physical or
psychological barriers
• unable to undergo MRI scanning (metal
implants, severe claustrophobia)
• unfit to undertake exercise according to
the American College of Sports Medicine
(ACSM) guidelines
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able to make entries, amendments or changes to patient
data on the eCRF. The trial dataset will be held and ana-
lysed by the Glasgow CTU. Investigators will not have
access to the full dataset until the trial is closed.
Study timeline
Baseline assessments
The CYCLE-HD study protocol timeline is shown in Fig. 1.
Baseline assessments will be undertaken on a non-dialysis
day at the NIHR-Leicester Cardiovascular BRU.
Cardiac MRI
The CMR scan protocol timeline in shown in Fig. 2.
Patients will be imaged on a 3 Tesla (3 T) CMR platform
(Skyra, Siemens Medical Imaging, Erlangen, Germany).
The CMR protocol will be similar to that previously
described but without contrast administration [46]. LV
volumes and mass will be quantified with epicardial and
endocardial contours of a contiguous stack of multiphase
ventricular short axis cines (10–12 slices, 8 mm slice
thickness, 25 % gap) at end-diastole and end-systole.
Native T1 and T2 mapping at mid-ventricular level will be
undertaken for tissue characterisation, with non-contrast
T1 mapping offering the opportunity to assess myocardial
fibrosis [47, 48]. Vasodilator stress with adenosine at an
initial dose of 140 μg/kg/min for three minutes will be
given and myocardial perfusion will be assessed with the
response in signal intensity on T1 and T2 maps compared
to baseline [49]. Adequate haemodynamic response is
assessed by either ≥10 % heart rate increase or ≥10 mmHg
decrease in systolic blood pressure. Adenosine dose may
be increased incrementally to an upper limit of 210 μg/kg/
min to achieve haemodynamic response if needed. Feature
tracking and/or tissue tracking will be used to assess sys-
tolic strain and diastolic strain rate [44]. Myocardial perfu-
sion reserve (the ratio of global myocardial blood flow at
rest versus stress) will be assessed using phase contrast
velocity mapping of the coronary sinus before and after
adenosine stress [50]. Aortic compliance will be assessed
by measuring distensibility of the ascending and descend-
ing thoracic aorta. Changes in the cross-sectional luminal
area of aorta in a 5 mm thick slice will be measured and
concomitant measurement of blood pressure at the time
of sequence acquisition will allow calculation of aortic dis-
tensibilty and pulse wave velocity [41]. Three point Dixon
images for quantification of thoracic visceral fat content
will be acquired in patients who tolerate the scan well.
Echocardiography
Patients will be scanned by an accredited sonographer
on a Phillips iE33 platform (Best, The Netherlands) in
the NIHR-Leicester Cardiovascular BRU. Assessments
will include: LV size and function; LV mass; relative wall
thickness and geometry as per the American society of
echocardiography guidelines [47]. In addition specific
focus will be paid to diastolic dysfunction and end-
diastolic integrated backscatter measurements that are
directly related to the presence of myocardial fibrosis
and validated in HD patients [51–55]. These data are
key to assessing the long term effect of exercise on myo-
cardial fibrosis in HD patients as the use of late gadolin-
ium enhancement on CMR is not possible due to the
risk of nephrogenic systemic fibrosis [56]. Speckle track-
ing for strain assessment will be also be undertaken.
Holter monitor
Patients will undertake 48 h Holter monitoring (Schiller,
medilog®AR12 plus/AR4 plus/FD5 plus, Baar, Switzerland)
that will start before dialysis and terminate just before the
subsequent dialysis treatment 48 h later. In a sub-study,
the intervention group will undergo a further 48 h Holter
recording that will start before a dialysis session and in-
cludes the cycling exercise intervention and continues for
the same time period afterwards. This will enable interim
analysis to ensure that there are no adverse rhythm distur-
bances associated with exercise in the intervention group.
Non-Invasive Cardiac Output Monitor (NICOM)
Patients will have cardiovascular parameters measured
by bioreactance prior to dialysis, using the NICOM
(Cheetah Medical, Maidenhead, UK) in-line with their
guidelines for use. This device assesses phase shifts in
transthoracic voltage when a high frequency current is
applied across the torso [57]. From this validated tech-
nique [58, 59] the NICOM provides readings of cardiac
output, stroke volume, heart rate, total peripheral resist-
ance, cardiac power and ventricular ejection time.
Blood sampling
Blood samples will be collected from the arterial needle
before dialysis. Thirty millilitres will be collected to be
centrifugated at 20 °C at 2500 × g for 15 min. Plasma will
then be pipetted into cryotubes and frozen at -80 °C in an
electronically monitored freezer for analysis in batches
throughout the study. All samples will be collected, stored
and disposed of in accordance with the Codes of Practice
as laid out by the Human Tissue Authority.
Physical function tests
Patient physical functioning will be assessed by the shut-
tle walk tests, the sit-to-stand-60 (STS60) test and the
short physical performance battery, all of which have
been used extensively as accurate measures of aerobic
capacity, lower leg strength and physical function in HD
patients [60–62].
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Fig. 1 CYCLE HD study protocol timeline
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Anthropometric measures
Patients will have measures of hip and waist circumfer-
ences, body weight and body composition. Body com-
position will be analysed prior to dialysis, using
bioimpedance spectroscopy (BIS). For this we will use
the Body Composition Monitor (BCM Fresenius Medical
Care, Bad Homburg, Germany), validated for use in HD
patients [63], allowing for interpretation of normally
hydrated lean and adipose tissues as well as excess fluid
[64, 65] and other variables.
Quality of life and physical function
Patients will complete the following questionnaires to cap-
ture data about physical activity and quality of life: Short
form-12 version 2 (SF-12) which has physical and mental
component scores; the EQ-5D-5L which provides a func-
tional index value and visual analogue score; the Palliative
Outcome Scale–Symptoms Renal (POS-S Renal) to assess
symptom burden; The Hospital Anxiety and Depression
Scale (HADS) to assess anxiety and depression levels; The
Leicester Dialysis Patients–Physical Activity Questionnaire
(LDP-PAQ), which assesses perceived physical activity, per-
ceived stage of change, perceived self-efficacy, self-reported
physical activity levels and perceived barriers to exercise
participation. Objective data on patient physical activity
levels will also be gained from tri-axial accelerometers
(Sensewear; BodyMedia, Inc. Pittsburgh, PA), which will
calculate steps taken, energy expenditure (kcALs) and aver-
age metabolic equivalents (METS).
Collection of routine clinical information
As part of routine clinical care, a number of parame-
ters will be collected on a monthly basis. These include
(but are not limited to) blood pressure, weight and
fluid removal for every dialysis session as well as bio-
chemical and haematological blood tests.
Follow-up assessments
Follow up visits are summarised in Fig. 1. A one-month
run-in period allows the exercise group to familiarise
themselves with intradialytic cycling. Three months after
this run in period (four months from baseline), interim
assessments will be conducted. This will involve all base-
line assessments except the CMR, echocardiogram and
NICOM. The control group will also undergo interim
assessments at month four.
Final assessments will be conducted for both exercise
and control groups after seven months. Assessments at
study completion will be identical to the baseline visit.
Following study completion, patients will be offered
the opportunity to continue with intradialytic cycling if
they wish and control patients will be offered the chance
to move to a shift where exercise intervention is avail-
able. We will also ask patients to complete a feedback
and evaluation form for ongoing development of study
and future service provision.
Sub-study
Additional informed consent will be sought after the first
CMR scan for ten control patients to be re-scanned using
an identical scan protocol to assess inter and intra-observer
variability and reproducibility of all scan parameters.
Investigation reporting
Cardiac imaging will not be reported until after the pa-
tient has completed the study so as not to influence the
study outcome. However life-threatening incidental find-
ings identified during scan acquisition will be reported
to the chief investigator, the data safety management
board (DSMB) and the sponsor, and a full report will be
issued to aid clinical care and ensure patient safety.
Image analysis
All scans will be anonymised and analysed off-line blinded
to patients’ data and treatment arm. CMR analysis will be
Fig. 2 Cardiac MRI Protocol. (4/3/2C, 4/3/2 Chamber; LV, Left Ventricular; SA, Short Axis)
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both visual and quantitative following international
recommendations [66]. Quantitative analysis will be
performed by a single operator using FDA approved
commercially available software. This will include: LV
mass(g); End-diastolic volume (ml); end-systolic volume
(ml); stroke volume (ml); and ejection fraction (%). All
volumetric data will be indexed to body surface area.
T1 and T2 values will be taken from a mid-short axis
slice of the LV by drawing epicardial and endocardial
borders [49]. LV strain and strain rate will be assessed as
previously described [44]. Endocardial and epicardial
contours will be manually drawn onto the end-diastolic
image and propagated and LV endocardial and epicardial
circumferential and longitudinal strain and strain rates
will be calculated.
Aortic distensibility will be analysed as previously de-
scribed [67]. The ascending thoracic aortic area will be
manually identified as a region of interest using JIM ver-
sion 6 (Xinapse software, UK) and graphically represented
against time. Aortic distensibility will be determined using
the validated formula:
maximum aortic area−minimum aortic areað Þ=
minimum aortic area X ΔPð Þ
ΔP is the brachial pulse pressure reading performed
during CMR [68].
‘Usual care’: haemodialysis
Haemodialysis is a form of renal replacement therapy
that replaces part of the excretory function of the kid-
neys by filtering waste, removing fluid and restoring
electrolyte and acid-base balance by transferring blood
from the body through a dialysis machine and returning
it to the body. ‘Adequate’ dialysis is often assessed by
calculating the clearance of small molecules during a
dialysis session and guidelines for minimum suggested
clearance exist [69]. This is only one measure of dialysis
‘adequacy’ however, and a dialysis machine only re-
places certain aspects of renal function and patients re-
ceive a number of additional interventions as part of
their ‘usual’ dialysis care. There are defined treatment
targets for blood pressure, calcium, phosphate, haemo-
globin and iron stores – including management of an-
aemia with erythropoietin stimulating agents (ESAs)
and intravenous iron infusions [69] in addition to mea-
sures of adequacy from small molecule clearance. Both
trial arms will continue ‘usual care’ aimed at achieving
these targets to allow assessment of the effects of intra-
dialytic exercise in addition to usual dialysis care.
Intervention: intradialytic exercise training
The intervention is a 6-month progressive intradialytic
cycling programme. The intervention group will use
specially adapted and calibrated exercise cycles (Letto
series; Motomed, Reck, Germany, see Fig. 3) three
times a week during dialysis, aiming for 30 min con-
tinuous cycling at a Rating of Perceived Exertion (RPE)
of 12–14 [70] adjusting resistance as required to pro-
gress training (Fig. 3). Our pilot exercise programme of
31 patients has been well tolerated with no adverse
symptoms reported in any of the exercising patients. It
is accessible to patients of different ages, gender, cul-
tures and ethnicities.
Progressive training will be allowed for patients unable
to complete 30 min continuous cycling, until this target
is achieved and patients will be allowed to complete
longer exercise bouts if they request. This individualised
style of exercise programme has been guided by patient
feedback during studies we have previously conducted
[71]. There will also be a run in period of one month,
again as a result of patient feedback, to enable individ-
uals to get used to the equipment, to build confidence
and to ensure they will be able to achieve the required
exercise intensity to derive a benefit before the 6 months
of ‘formal’ training begins. Patients will be regularly vis-
ited throughout the period of study to ensure compli-
ance and also progression using a specially designed
RPE-guided incremental exercise test to confirm appro-
priate exercise intensity.
Sample size calculation
A study by London et al. showed a 10 % decrease in LV
mass (≈29 g) translated into a 28 % decrease in mortality
risk from cardiovascular causes over a five-year follow-up
Fig. 3 Patient undertaking intradialytic cycling on specially
adapted cycle
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of a cohort of HD patients (a 1 g decrease translated to a
1 % decrease in CV mortality risk) [48]. A previous study
of exercise in HD patients has shown a reduction in left
ventricular mass index and increase in left ventricular
ejection fraction (LVEF) assessed by echocardiogram, but
not to significance [72]. In a study of the benefits of exer-
cise training in 11 hypertensive elderly patients, 6 months
of exercise (walking, jogging or cycling training) produced
a 15 g difference in LV mass between the intervention
group and controls [73]. CMR data from an RCT that
assessed the benefits of frequent HD on LV mass in HD
patients [74] provides an estimate for the standard devi-
ation (SD) for change in LV mass of 25.9 g for the control
group; we will assume that the SDs are similar in both
groups. A difference (of change from baseline) between
the two groups in LV mass of 15 g is deemed to be clinic-
ally significant. We have assumed an intra-cluster correl-
ation coefficient of 0.02. From previous pilot work [75] we
expect a drop-out rate of 10 % from exercise intervention.
To have 80 % power to detect a difference between treat-
ment groups of 15 g, with group standard deviations of
25.9 g, 65 patients are required in each group, accounting
for a 10 % study attrition rate.
Statistical analytic approach for primary outcome
The primary outcome is the change from baseline at six
months in LV mass. Change from baseline will be calcu-
lated for each subject as the value at month six minus
the baseline value. Differences in primary outcome
measure between the intervention groups (exercise and
control) will be tested within a linear mixed model con-
taining a covariate for the intervention group and a ran-
dom effect for the cohort (centre and shift). These models
may be further adjusted for any imbalances between the
intervention groups with respect to the baseline character-
istics. All statistical analyses will be performed by a bio-
statistician from the Robertson Centre for Biostatistics,
University of Glasgow.
Safety reporting
Due to the nature of ESRD and of HD, patients are likely
to experience adverse events throughout the course of
the study. Patients on HD have a large burden of co-
morbid disease and, acute illness resulting in hospitalisa-
tions, new medical problems and deterioration of exist-
ing medical problems are expected throughout the study
period.
All adverse events (AEs) or adverse reactions (ARs)
and serious adverse events (SAEs) or serious adverse
reactions (SARs) will be recorded from the time a pa-
tient enters the study to the final study visit. Each AE or
AR will be considered for severity, causality and expect-
edness and may be reclassified as an SAE or SAR de-
pending on the circumstances.
An SAE is any AE that:
 is life threatening
 requires hospitalization or prolongation of a hospital
admission
 results in a persistent or significant disability or
incapacity
 is a congenital anomaly
 results in death
All unexpected SAEs will be reported to the Glasgow
Clinical Trials unit (CTU) within 7 days of awareness of the
event, including a report assessing event intensity and likeli-
hood of causality (see below) from the chief investigator or
suitable nominated investigator. Study investigators will
report all unexpected AEs, ARs, SAEs and SARs to the clin-
ical trials unit, the sponsor, the Research Ethics Committee,
and the Data Safety Management Board (DSMB).
Unexpected non-serious AEs will be assessed by the
chief investigator, and should include an assessment of
intensity and causality (see below), with reports being
made within 14 days. These will be reported to the CTU
and if appropriate to the sponsor, the Research Ethics
Committee, and the DSMB.
The following guidance will be used to assess the in-
tensity of an AE or an AR:
 Mild: The patient is aware of the event or symptom,
but it can tolerate it easily
 Moderate: The patient experiences sufficient discomfort
to interfere with or reduce his or her usual activities
 Severe: Functional levels are significantly impaired
by the event such that patients can no longer carry
out usual activities, or life is at risk from the event
The following guidance will be used to assess causality
between an AE or AR and study participation:
 Unrelated: A causal relationship can definitely be
excluded as another documented cause of the
AE/AR is most plausible
 Unlikely: A causal relationship is improbable and
another documented cause of the AE/AR is most
plausible
 Possible: A causal relationship is clinically/
biologically plausible and there is a plausible time
sequence between AE/AR and study participation
 Probable: A causal relationship is clinically/biologically
highly plausible and there is a plausible time sequence
between onset of the AE/AR and study participation
Data safety management board
The DSMB will be an independent group of experts,
consisting a nephrologist, a cardiologist, lay member and
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a statistician, who will monitor patient safety and treat-
ment efficacy data while the clinical trial is ongoing; the
primary mandate of this committee is to protect patient
safety. If adverse events of a particularly serious type are
more common in the experimental arm compared to the
control arm, then it would be within the remit of the
DSMB to consider termination of the study if the risks
outweigh the benefits for patients. All SAEs deemed to
have a causal relationship with the intervention will be
reviewed by the DSMB for individual consideration of
patient safety and continuation within the trial.
Intervention fidelity and monitoring
Experience to date with our unit based exercise
programme has shown this programme to work with very
small dropout rates of <5 % and a number of studies of
similar size with exercise interventions of 6–10 months
report very good compliance (up to 99 %) with compar-
able dropout rates [71, 72]. Temporary noncompliance
(e.g. intercurrent illness, holiday) will be allowed for by
adding missed exercise sessions onto the end of the study
period. Apart from the exercise intervention in the study
group, usual care will be continued for both groups. The
involvement of the nursing staff with the study will help
aid compliance and monitoring and there will be frequent
contact between patients and research staff.
Discussion
The primary aim of this study is to assess the effect of a six
month programme of intradialytic exercise on LV mass as
assessed by CMR. The cluster randomization design was
chosen for the advantages in reducing exercise contamin-
ation of the control group and to ensure demographic
homogeneity. There is the possibility that this could create
selection bias if patients are aware which cohorts have been
randomised to intervention and control before they are
enrolled, but this will be minimised by not revealing the
method of randomisation to patients until after they have
consented to participation and completed all baseline as-
sessments. This study will provide the opportunity to evalu-
ate the effects of a structured programme of intradialytic
exercise on a number of secondary outcomes. Whilst clin-
ical outcome data will be collected, this study is not de-
signed to evaluate the effects of exercise on mortality.
CMR used in this study is the gold standard technique
for the quantification of LV mass, volumes and function.
We anticipate it will be technically challenging to obtain
high quality images for some patients who may struggle
to lie flat for long periods or who find breath holding
difficult. The CMR protocol has been carefully designed
to acquire all desired images in the most efficient way
possible and have pioneered techniques that allow shorter
scan times, with the primary outcome measure obtained
early in case of premature scan termination. The CMR
radiographers at the NIHR-Leicester Cardiovascular BRU
have many years’ experience obtaining scans from patients
with similar burdens of co-morbid disease [45, 76, 77].
The increased signal noise ratio obtained at 3 T allows the
faster acquisition of cine images (4–5 s) for patients who
are poor at breath-holding and free-breathing techniques
can also be used with acceptable image quality.
There are some data suggesting interdialytic exercise may
yield superior cardio-respiratory adaptations to intradialytic
exercise programmes, but with significantly higher drop-
out rates [18, 19]. Given the proven benefits of intradialytic
exercise programmes compared to control patients and the
superior adherence rates [18], pragmatically an intradialytic
exercise programme was chosen as it is the most likely to
be translated successfully into clinical practice.
The adoption of intradialytic exercise programmes
into clinical practice has been slow and this has, in part,
been attributed to patient and clinician concerns regard-
ing safety [78–82]. The study is designed so that interim
analysis will provide data on the arrhythmogenic poten-
tial of intradialytic exercise. This should in turn help to
alleviate patient and staff concerns regarding the safety
of exercise on dialysis.
Conclusion
This study will test the hypothesis that an intradialytic
programme of exercise leads to a regression in left ven-
tricular mass, an important non-traditional cardiovascu-
lar risk factor in end stage renal disease. We will also
evaluate the efficacy, feasibility and safety of an intradia-
lytic exercise programme using a number of secondary
end-points. We anticipate that a positive outcome will
lead to both an increased patient uptake into established
intradialytic programmes and the development of new
programmes nationally and internationally.
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